
Keith Loria
Keith Loria is a contributing writer to Medical Economics.
Articles by Keith Loria


The researchers identified 32 proteins associated with rapid declines in lung function.

The company recently announced promising results from its phase 2a clinical of an agent that the company says is the first to target Traf2- and NCK-interacting kinase, or TNIK for short.

Black patients are less likely than White patients to get the molecular testing that can led to immunotherapy and other more advanced treatments.

Libtayo monotherapy nearly doubled the median overall survival and lowered the risks of death and disease progression.

“Immunity debt” may be the explanation

The data revealed that 17.1% of patients experienced grade 3 or greater arrhythmias.

Researchers that clinical guidelines highlight the possibility of chronic obstructive pulmonary disease and other conditions masking early symptoms of lung cancer.

A nomogram based on four pulmonary factors is helpful but not a substitute for clinical judgment, say the authors.

Pulmonary complications remain a major cause of morbidity and mortality in rheumatoid arthritis-associated interstitial lung disease, despite increasing research interest in the condition.

A new study conducted by researchers at the United Therapeutics Corporation in Durham, NC, looked to characterize PH-ILD disease burden by analyzing healthcare resource utilization (HCRU) and cost data.

USC researchers found a link between childhood exposure to nitrogen dioxide well below EPA limits and bronchitis symptoms in adults.

New research published in Nature Scientific Reports revealed that people with MS are more prone to experience a short-term reduction in disability and brain lesion volume after receiving stem cell therapy.


A new study out of Germany, published in Science Translational Medicine in June, looked at peripheral blood mononuclear cells and serum collected from two independent cohorts of patients with MS to identify three endophenotypes of the disease.

Researchers of a JAMA Network study observed that RSV patients seemed to be older than usual and globally sicker than usual requiring advanced respiratory support and intensive care.

From the cohort study, 67 participants developed Multiple Sclerosis after enrollment.

Up until recently, no single study had validated the relationship between lung volume and tissue and static respiratory system compliance at the applied positive end-expiratory pressure.

A new study looked to show how frequent non-coding FOXF1 gene deletions that interfere with important DNA regulatory regions can lead to a rare, lethal, genetic lung disease which causes respiratory failure in many newborns and infants.

While plenty of studies have been done looking at how blood cells function within bone marrow, new research looks deeper at other cells, and resulted in the collaborators creating a Bone Marrow Atlas.

Early efficacy data from a phase 2a safety trial on the subject was presented during an oral session at the American Thoracic Society 2024 International Conference in May.

The recent DUO trial, a global Phase III study, compared the efficacy and safety of duvelisib, an oral PI3K inhibitor, with ofatumumab, an anti-CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had previously undergone at least one therapy.

A new study published May 2024 in Scientific Reports examined the changes in morphology and antibacterial activity in four honey varieties from Hungary matched against respiratory pathogens.

Christel Nielsen, associate professor at Lund University, gathered a team of researchers to find the relationship between tattoo ink exposure and malignant lymphoma and lymphoma subtype risk.

A new study published April 2024 in the JAMA Network looked to establish a link between burn pits and higher respiratory and cardiovascular disease in veterans, responding to widespread concern from veterans.

Although chronic respiratory diseases remain the third leading cause of mortality, they have received less attention from the global community.

Rapidly progressing interstitial lung disease in anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is known for its high death rate because it worsens quickly and causes breathing difficulties within three months of initial lung symptoms. However, there isn't much information about the timing between the diagnosis of ILD and MDA5 antibody-positive DM because most research focuses on either the frequency or the death rates rather than the timing of onset.


The Choosing Wisely campaign has helped with overscreening and overtreatment. Some experts say better management of end-of-life care and value-based payment would also help steer oncology away from care with poor cost-benefit ratios.

The evidence for active surveillance is stronger, but advances in imaging have improved the ability to distinguish between indolent and aggressive forms of prostate cancer.
